Type 1 diabetes mellitus (T1DM) is a chronic metabolic disorder characterized as an autoimmune disease in which the body specifically attacks pancreatic β-cells. This results in insulin and amylin deficiencies, which produces chronic hyperglycemia. 1 Insulin injection therapy is effective in many patients, but it is imperfect. People with T1DM face a trade-off among glycemic control, lifestyle flexibility, and therapy effort. Using current therapy options, near normoglycemia can be achieved only by patients at the expense of lifestyle flexibility and increased therapy effort. Because of this excellent glycemic control remains more of an aspiration than a reality.
achieved; therefore, the focus is on finding methodologies to lower postprandial glucose excursions.
In healthy individuals, insulin and amylin are cosecreted from the pancreatic β-cells in response to a meal. 9 Insulin acts to inhibit hepatic glucose output through inhibition of glucagon from the pancreatic α-cells and stimulates the uptake of glucose into peripheral insulin-sensitive cells. Amylin modulates appetite, suppresses glucagon secretion, and slows the rate at which nutrients are delivered from the stomach to the small intestine for absorption. Amylin mitigates the influx of endogenous and exogenous glucose into the circulation and thus improves the rate of glucose clearance incurred by insulin. 10, 11 In T1DM however, both amylin and insulin production are decreased significantly due to the death of β-cells. Patients exhibit a paradoxical postprandial hyperglucagonemia in which endogenous glucagon levels are elevated in the portal circulation and insulin levels are reduced. Administration of exogenous insulin alone does not normalize the portal glucagon to insulin ratio; the liver continues to release glucose into the circulation, resulting in hyperglycemia. 12 It seems logical then to include both insulin and amylin in the fight against postprandial hyperglycemia in T1DM. Pramlintide, a soluble, nonaggregating, equipotent synthetic analog of amylin, is approved by the FDA and used to treat T1DM patients who are unable to obtain near-normoglycemia with insulin therapy alone. 13 In 2012, a study was done using closed-loop control of insulin along with pramlintide treatment in young adults and adolescents, who demonstrated marked improvements in regulation and significant reduction in glucose postprandial peak and a delay of peak glucose occurring more than 1 hour later than the placebo patients. 14 The meal's immediate impact is lowered dramatically and spread out making glucose control much improved. 14 The controller was a proportional integral derivative (PID) controller using model-based insulin feedback. 15 Results looked very promising but were essentially preliminary with only 8 patients.
In the closed-loop study above, 14 there were no incidents of hypoglycemia over the 2 days. Weinzimer et al 14 gave no premeal boluses to the patients. All insulin delivery was due to automatic feedback based on actual glucose readings. Many other studies [16] [17] [18] [19] [20] [21] [22] [23] have reported that pramlintide resulted in hypoglycemia. However, the cause of hypoglycemia was a result of the interplay between insulin and pramlintide. These studies when exploring pramlintide dosing did not investigate lower insulin dosages. Pramlintide mechanisms allow for postprandial glucose to be significantly reduced, thus requiring a lower insulin dosage than previously used. What is required is a better model to help calculate new premeal boluses in the presence of pramlintide, test other dose regimens, and test the possibility of use in a better model-based controller.
The most detailed model for pharmacokinetics and pharmacodynamics (PK/PD) for pramlintide 13 is based on using intravenous (IV) pramlintide doses. The most recent model 24 had PD based on 1 set of 15 patients using 1 concentration of SC pramlintide given at only 1 time point relative to a single meal and insulin bolus. The model did not include PK of pramlintide but instead had parameters for the gastric emptying model modified proportionately by initial dosage of pramlintide and amount of glucose present in the meal. 24 The study presented in this article was undertaken to develop a PK/PD model based on an existing glucose-insulin model 25 with the addition of the drug pramlintide. This model is based on SC lispro (short-acting) insulin 26 and pramlintide administration along with a working meal model. Pramlintide PD was based on the mechanisms of pramlintide and its effect on plasma glucose at the postprandial period. Parameter fits and model validation were achieved using data found in the literature, which includes 6 articles with 27 data sets. 7, 13, 17, [21] [22] [23] We sought to create a glucose-insulin-pramlintide model that could be used to evaluate strategies incorporating pramlintide into T1DM therapies.
Model
The proposed model is based on parameters and equations from 3 articles. 20, [25] [26] This model consists of a glucoregulatory and insulin action subsystem model 25 with SC lispro (short-acting) insulin kinetics (insulin subsystem) 26 substituted. The pramlintide PK is taken from a previous study 20 with the SC pramlintide PK adapted from SC insulin PK. 26 Several changes to the original models 20,25-26 have been made. A meal correction, a change in t max,G , and the addition of a meal delay (n θ ) all in the presence of pramlintide have been added to the glucoregulatory subsystem found in Hovorka et al 25 . The insulin action subsystem of Hovorka et al 25 ) , which is the delay from the time pramlintide is administered to the time an effect of pramlintide is seen on blood glucose has also been added. The model outline is shown in Figure 1 .
Glucose Subsystem
The first 2 states are the total mass of glucose in each compartment, scaled by the patient weight. 25 The material balance around the first compartment includes renal clearance (F R ), glucose infusion (u G ), and endogenous glucose production (EGP) (which is constrained to be positive),
where G 1 and G 2 represent the masses of glucose in the accessible (where measurements are made) and nonaccessible compartments, k g represents the transfer rate constant from the nonaccessible to the accessible compartment, V G represents the distribution volume of the accessible compartment, G is the (measurable) glucose concentration (mmol/L), and EGP 0 represents endogenous glucose production EGP extrapolated to the zero insulin concentration.
F 01 c is the total non-insulin-dependent glucose flux corrected for the ambient glucose concentration 
F R is the renal glucose clearance above the glucose threshold of 9 mmol L −1
A second order pulse response is used as the meal disturbance, 25
where t max,G is the time-of-maximum appearance rate of glucose in the accessible glucose compartment, D G is the amount of carbohydrates digested, and A G is carbohydrate bioavailability.
Insulin Subsystem
SC lispro (short-acting) insulin PK, 26
where the insulin dosage is represented by u Insulin , the elimination rate constant is k ei , Plasma I is the measurable insulin compartment, and kSQ is1 , kSQ is2 , and kSQ if are rate constants of the slow and fast compartments, respectively. LD ai and LD bi represent Michaelis Menten degradation kinetics of insulin. I is the (measurable) plasma insulin concentration in mU/L.
Insulin Action Subsystem = − + (16) where I 1 , I 2 , and I 3 represent the (remote) effects of insulin on glucose distribution/transport, glucose disposal, and endogenous glucose production; 25 k ia1 , k ia2 , and k ia3 represent deactivation rate constants, and S fIT k ia1 , S fID k ia2 , and S fIE k ia3 represent activation rate constants, which include the insulin sensitivities of distribution/transport, disposal, and EGP, respectively. Insulin sensitivities were taken from Palerm, 15 who found that nominal insulin sensitivities were generally too high for adolescents and older people (these generally result in insulin/carb ratios of 1/25 or so); these sensitivities have been reduced by one-half. 15 
Pramlintide Subsystem
IV pramlintide PK equations were taken from a previous pramlintide study 20 
where the pramlintide dosage is represented by u Pram , the elimination rate constant is k ep , Plasma P is the measurable pramlintide compartment, kSQ P is a rate constant, and k p12 , k p21 , k p23 , and k p32 are transfer rate constants. P 2 and P 3 represent possible effects of pramlintide on glucose. P is the (measurable) plasma pramlintide concentration in mcg/L, p θ is a transport delay of pramlintide between its administration and its effective site resulting in an effective concentration, P eff .
Pramlintide Action Subsystem
Pramlintide, when in the system, affects the peak meal absorption time (t max,G ; equation 23). Changes in t max,G cause a shift in the meal which must be accounted for and corrected, as seen in equations 24 and 25. 
where t sw is the time at which t n and P P 
where p θ is a transport delay of pramlintide between its administration and its effective site resulting in an effective concentration, P eff . n θ is a delay on the current meal that occurs in the presence of pramlintide, t max,G,old is the peak meal absorption time at the previous time point, t max,G,new is the peak meal absorption time at the current time point, k lag is the lag constant that acts on t max,G,old in the presence of pramlintide, D G is the amount of glucose given as a meal, A G is the bioavailability, and P min is the minimum pramlintide concentration.
Model Constants and Parameters
Model quantities were divided into model constants from the literature ( Table 1 ) and model fitted parameters from this study ( Table 2) .
Methods

Introduction
All modeling, parameter estimations, and simulations were performed using MATLAB® 2012a (Mathworks, Inc, Natwick, MA). Original data from studies were not available. Therefore, the program GraphClick© (Arizona Software, Zurich, Switzerland, http://www.arizona-software .ch/graphclick) was used to get data points of mean values presented in published graphs.
Data Sets
Six previously published articles 7,13,17,21-23 with 27 data sets were used for the modeling of both pramlintide SC PK and PD. Colburn et al 21 and Fang et al 13 were used for predicting IV PK. Kong et al 23 was used for fitting SC PK, and Kolterman et al 22 was used for predicting SC PK. Weyer et al 7 was used for fitting PD, and Thompson et al, 17 Kong et al, 23 Kolterman et al, 22 and Fang et al 13 were used for predicting PD.
The first article, Colburn et al, 21 included 6 data sets and was used to test IV PK of pramlintide. This study included 24 subjects with T1DM. The 24 subjects were divided into 3 pramlintide dose groups of 8 subjects each: group A was given 30 mcg, group B was given 100 mcg, and group C was given 300 mcg. Patients in each dose group underwent a 2-period IV bolus-versus-infusion crossover. The study design included administration of usual insulin dose 30 minutes before pramlintide administration. A standardized meal was given 30 minutes after pramlintide dosage. Bolus pramlintide was given as an IV push over 2 minutes, and the infusion was given over a period of 2 hours.
The second article, Fang et al, 13 included 6 data sets and was used to test our model's IV pramlintide PK/PD model. This study included 25 male subjects with T1DM. This study followed the same protocol used by Colburn et al. 21 The third article, Kong et al, 23 which included 4 data sets, was used to fit SC pramlintide PK and validate PD. This study included 11 men with T1DM. Gastric emptying was measured using low-activity radioactive markers (99mTc) were attached to the surface of the subject's skin, anteriorly and posteriorly. Thirty minutes before they were due to eat, the patients injected themselves with their usual morning insulin, and 15 min later they injected the study drug (either placebo or 30, 60, or 90 mcg pramlintide) subcutaneously. At 0 min, within 10 min, they ate a standard meal consisting of a pancake, labeled with 3MBq nonabsorbable Tc-99m-ion exchange resin, and a low fat milkshake containing 3-OMG. The meal consisted of 62.5 g of carbohydrates. Gastric emptying images were obtained for the next 8 hours. At 240 min the subjects ate a similar meal.
The fourth article, Kolterman et al, 22 included 3 data sets and was used to validate SC PK/PD. This study investigated the effects of a 14-day period of amylin replacement therapy on responses to a standardized IV insulin infusion and a liquid Sustacal meal in amylin-deficient T1DM subjects. This study included 84 subjects; 22 subjects were given a placebo, 18 were given 30 mcg of pramlintide, 23 were given 100 mcg of pramlintide, and 21 were given 300 mcg of pramlintide. The pramlintide dosage was given 30 minutes before the liquid Sustacal meal of 49.5 g of carbohydrates, and the insulin infusion of 40 mU kg -1 hr -1 for 100 minutes was given at the same time. Blood glucose, lactate, glucagon, insulin, catecholamines, calcium, and potassium levels were measured. It should be noted that plasma glucose concentrations were not given prior to the meal resulting in the fitting of the baseline glucose concentrations at t = −30 min (time insulin and pramlintide were administered).
The fifth article, Weyer et al, 7 included 5 data sets and was used to fit our model's PD. Lispro insulin and regular insulin were both used in this study. However, only lispro insulin was used as our model expresses the kinetics of only lispro insulin. This study included 21 subjects. Subjects received 1 of 5 treatments (a SC injection of placebo at −15 min or 60 mcg pramlintide) at −15, 0, +15, or +30 min relative to the standardized breakfast according to a randomized sequence, after an overnight fast. The meal and insulin dosage (6-6.3 units) were given at 0 min. It should be noted for the pramlintide dosage given at t = −15 min relative to the meal plasma glucose concentrations were only given from t = 0 min (time meal and insulin were administered), resulting in the fitting of the baseline glucose concentration for this pramlintide dosage. The final article, Thompson et al, 17 included 3 data sets and was used to validate our model's PD. This study was a double-blind, randomized, placebo-controlled, parallelgroup, fixed-dose study comparing the effects on 24-hour plasma glucose profiles, PK, and drug tolerance of 3 doses of pramlintide and placebo administered 4 times a day for 14 days to patients with T1DM. Insulin was given 30 minutes prior to the meal, and pramlintide dosage of 0 mcg (placebo) (42 subjects), 10 mcg (43 subjects), 30 mcg (41 subjects), or 100 mcg (42 subjects) was given 15 minutes before the meal. The meal was a standardized Sustacal meal of 75 g of carbohydrates. It should be noted that at 9:00 pm a snack of unknown quantity was given to the subjects; as a result, this snack was not included in predictions.
Performance Metrics
Root mean square error (RMSE) was used as measures of goodness of fit. Data are reported as mean ± standard error of the mean,
where x is our model's estimate, x ref is the reference value and n is the number of samples.
Modified Hovorka Glucose-Insulin Model
The original modified Hovorka [25] [26] with glucose and lispro insulin (rapid acting) PK/PD was tested on clinical data 7,17,22-23 using known meal amounts. Insulin amounts were fitted for all data except Weyer et al, 7 where insulin amount was known.
Pramlintide Pharmacokinetics
IV pramlintide kinetics 20 were added to the modified Hovorka 25, 26 and tested with clinical data 13, 21 shown in Figures 2 and 3 . Next, the IV pramlintide kinetics 20 were converted to SC kinetics by adapting the SC kinetics of insulin. 26 The original model had 7 parameters to fit. Parameters were fit to SC PK data. 23 These parameters were fit by first linearizing the model. Then, using the system identification toolbox in MATLAB, a gray-box model was created by using the "idgrey" function. Estimating parameters was done using the "greyest" command, which estimates a linear gray-box model, using time or frequency domain from experimental data. Least squares optimization was used to obtain final parameter estimates. Two of the 3 compartments were removed based on null parameter estimates. Resulting in 1 compartment with 1 added parameter, k SQp . High and low parameter estimates were found by using least squares optimization 1 standard deviation from the mean. PK was validated using data found in Kolterman et al. 22 Pramlintide kinetics seem to change over time; 22 to address this issue the volume at the pramlintide active site (V P ; equation 21) was fit using least squares optimization.
Pramlintide Pharmacodynamics
Glucose parameters most likely to undergo changes by pramlintide were scrutinized. Three parameters were chosen to be tested: EGP , k g and t max G , , found in equations 1, 2, and 6. These parameters were tested using a linear PD equation and fit to PD data 7 using least squares optimization. A time delay on the meal, a transport delay to the effective pramlintide compartment, and a minimum threshold concentration for pramlintide 23 were also tested. High and low parameter estimates were found by using least squares optimization 1 standard deviation from the mean. Validation of the model was done using other experimental data. 17, [22] [23] Last, a study containing IV pramlintide administration 13 was used as a prediction for PD.
Modification of the peak meal absorption time (t max,G ) equation 23 in this model affects not only dynamics but the magnitude of the meal uptake, which shows the process sensitivity of the second order pulse response used as the meal disturbance found in Hovorka et al, 25 equation 6. For this system, it is critical that the total meal does not change. If you modify the peak meal absorption time (t max,G ) without making a correction, you will get a different final meal amount than what was initially given. This can be seen in Figure 4a , where a step change in the time constant occurs at t = 20 min. Here different final meal amounts occur for different time constants (t max,G ). In Figure 4b you can see the different meal consumption at the peak meal absorption time change (t max,G ); this is the gap that needs to be compensated for mathematically to get a total meal consumed that is the equal to the amount that is initially stated. In Figure 4c the same step response that was done in 4a shows the mathematical correction for the gap where final meal consumption is equal to the initial meal given with varying peak meal absorption times (t max,G ).
Results
Modified Hovorka Glucose-Insulin Model
Fitting the various placebos found in the data tested the modified Hovorka model [25] [26] (Tables 3 and 4 ; Figures 5 to 9 ). Fitted RMSE values range from 4.64 to 25.74 mg/dL.
Intravenous Pramlintide Pharmacokinetics
A study containing IV pramlintide PK 20 proposed a 3-compartment model to represent pramlintide kinetics. This model was added to the modified Hovorka glucose-insulin physiological model [25] [26] and compared to experimental data. Two independent studies 13, 21 contain experimental data for both a bolus and infusion (IV) of 30, 100, and 300 mcg doses of pramlintide that were compared to the IV pramlintide PK model 20 (Figures 2 and 3 and Table 5 ). The goodness of fit for IV pramlintide PK has RMSE values range from 6.44 to 604.41 pmol/L.
Subcutaneous Pramlintide Pharmacokinetics
SC pramlintide kinetics were adapted 26 and added to IV kinetics. 20 Based on null parameter fits the model was reduced from a 6-compartment model to a 4-compartment model (Figure 1 ). Data from Kong et al 23 were used to fit parameters ( Table 2) ; these fits are shown in Figure 6 . Fitted RMSE values range from 5.24 to 10.66 pmol/L. The fit parameters were then used as predictions 22 (Figure 7 ). Predicted RMSE values range from 1.98 to 10.39 pmol/L. Kolterman et al 22 showed a change in kinetics after 14 days. To compensate for this change, it was hypothesized that this change occurs due to a change in volume at the active site. The value of V p (the volume at pramlintide's active site) was fitted 22 for kinetics at day 14 (Table 6 ). Fitted RMSE values range from 2.99 to 11.71 pmol/L.
Pramlintide Pharmacodynamics
Pramlintide PD were tested using a linear PD equation on 3 parameters: EGP , k g , and t max,G . EGP and k g did not produce desired results (results not shown). A change in t max,G based on effective pramlintide concentration,P eff and a lag constant, k lag along with a lag on the meal disturbance, n and the inclusion of a transport delay on pramlintide, p θ afforded a desired PD effect. These parameters were fitted 7 and shown in Table 2 . Goodness of fit is shown in Table 3 and Figure 5 . Fitted RMSE values range from 10.48 to 28.31 mg/dL. Fitted parameters were then used as predictions for Kong et al, 23 a study done with 2 meals, the first with pramlintide and the second without (Table 3 and Figure 6 ), Kolterman et al, 22 a study done after 14 days of continuous pramlintide use (Table 4 and Figure 7 ), Thompson et al, 17 a study done over 24 hours using pramlintide in 3 meals (Table  4 and Figure 8 ), and Fang et al, 13 a study using IV pramlintide (Table 4 and Figure 9 ). The error bars shown in graphs are not the standard deviations but the variation of the individual patient data. Standard deviations were not given, and error bars in the original article were generated using an in silico patient population. Predicted RMSE values range from 17.02 to 42.76 mg/dL. Fang et al, 13 which has its own PK/PD model for IV pramlintide, was used as a comparator for our predictions ( 
Discussion
A new in silico model of the glucose-insulin-pramlintide regulatory system has been presented. The modified Hovorka glucose-insulin physiological model [25] [26] was rigorously tested using placebo data. This model performed remarkably; this is especially evident with Weyer et al, 7 where insulin dosages are kept as constant as possible. Inserting this information into the glucose-insulin model yielded excellent results with an RMSE value of 4.64 ± 0.97.
The first addition to the modified Hovorka model was an IV pramlintide PK found in a previous study 20 which was tested using 2 clinical studies; 13, 21 results are shown in Table  5 and Figure 1 ). An explanation for this is that pramlintide is approximately 32% smaller than insulin, and enters through the SC layer more rapidly. Parameters were fitted using data sets from Kong et al. 23 A step response of both the IV and SC pramlintide PK indicated a time lag of approximately 55 minutes in the SC system. Results are shown in Tables 3 and 4 
and Figures 6 and 7.
Kolterman et al 22 showed variability in PK of pramlintide after 14 days of use and suggested that the bioavailability varied from dose to dose and acted independently over time. Investigation showed that by changing the volume at pramlintide's active site (V p ) predictions improved considerably. One possible explanation to this is that the volume at the active site is changing over time based on multiple parameters such as cardiac output, fluid loading, and cell permeability. Results are shown in Table 6 . Altered kinetics are used in Kolterman et al 22 and directly affect PD (Figure 7 and Table 4 ). 22 The top shows the placebo fits, the middle shows pharmacodynamics predictions, and the bottom shows pharmacokinetics predictions of 30, 100, and 300 mcg pramlintide doses, left, middle, and right, respectively. Model prediction is represented by the solid line, experimental data points are represented by the dotted line, and the standard deviation of the experimental data is represented by the dashed line.
Pramlintide has 3 mechanisms: (1) modulates appetite, (2) suppresses glucagon secretion, and (3) slows the rate at which nutrients are delivered from the stomach to the small intestine for absorption. 10, 11 The first mechanism was disregarded because it is related to the amount of food consumed, not to the dynamics after ingestion. The second mechanism is pramlintide's action on EGP in which glucagon secretion is suppressed causing lowered EGP. For this mechanism we chose to focus on parameters EGP and k g (see Figure 1 ). Where EGP is endogenous, glucose production and k g is the transfer rate constant from the nonaccessible to the accessible compartment. The third mechanism we focused on the parameter t max,G , which is the peak time of glucose absorption along with an added meal delay, n θ .
When a linear effect of pramlintide on EGP and k G was tested, the resulting fit wasn't adequate (results not shown). A possible reason why these parameters didn't give us desired results is because the hyperglucagonemia experienced postprandially in T1DM is not captured by this model explicitly. 25, 26 A strict meal delay, n θ was added when pramlintide is present in the system. It was found in 2 studies 13,23 that a meal delay occurs in the presence of pramlintide and also proved relevant in our model. In Kong et al 23 2 meals were given, the first with pramlintide, the second without. It was found in the study that no meal delay occurred, the same is true in our model, pramlintide must be present beyond a specific P min threshold to incur a delay on the meal (n θ ) or a change in the peak meal absorption time (t max,G ). The parameter, P min represents the minimum pramlintide concentration to impose an effect of plasma glucose, which was postulated by Kong et al 23 to be 10 pmol/L. However, when testing pramlintide dosage of 10 mcg presented in Thompson et al 17 (in which the lowest pramlintide plasma concentration is ~4.3 pmol/L) a pramlintide effect on plasma glucose occurs. P min was thus assumed to be a value below 10 pmol/L. However, it must be higher than the highest concentration during the second meal in Kong et al. 23 This is seen in the pramlintide dose of 100 mcg where P min must be at least 3 pmol/L to ensure no meal delay occurs for the second meal.
Slowing of gastric emptying is known to occur with pramlintide 1, 23 and was included in our model as a k lag that acts on t max,G linearly with respect to pramlintide concentration. A correction to the original meal disturbance equation 6 has to be done with changing t max,G values as seen in equations 24 and 25. The original error can be seen in Figure 4a , the gap change is depicted in Figure 4b , and the meal correction is depicted in Figure 4c . The implemented gap correction using discretized form of equation 24 had approximately 10% inherent error using a sample time of 1 minute.
Our model also includes a pramlintide transport delay to allow the drug when administered to enter the system and reach its active site. This is demonstrated in the study Weyer et al 7 in which pramlintide is administered at t = −15, 0, 15, and 30 minutes relative to the meal. It is evident at t = 15 and 30 minutes that pramlintide does not incur a meal delay or slowing of gastric emptying until approximately 9 minutes after pramlintide administration.
Thompson et al 17 provided the stiffest challenge to our model having 3 separate meal disturbances, insulin doses and pramlintide doses occurring in 1 in silico run. For this data set the results are mixed (see Figure 8 and Table 4 ). Our model appears to have a more pronounced pramlintide PD than what was experienced by the patients. Also, the underlying assumption that the patients' metabolic rate and meal uptake are identical for each meal may be incorrect. Any mismatch in the first meal will cascade to the following meals. These data seem to be at the edge of the model's capability, and it should be noted that these data were predicted, not fitted.
The final SC PKPD model had its PD parameters fitted using the 4 data sets from Weyer et al 7 since this is the official labeling data for pramlintide used by Amylin Pharmaceuticals. All other results are predictions. 13, 17, [22] [23] Parameters were fitted to meet mean data values for each data set, while upper and lower extremes were fitted to obtain parameter sets for those patient types. All parameters fitted were clearly correlated and show clear trends (see Table 2 ) and should not be considered independent and normally distributed.
A runs test was done on Weyer et al 7 fitted parameters to determine randomness in residuals by looking at values determined as positive and negative numbers. 27 Runs are a series of positives or negatives. Data found to be structured are said to have autocorrelation, which suggests that the model does not have enough information to accurately describe the system. 27 Pramlintide (60 mcg) at t = −15 min of the Weyer et al 7 data set was found to have autocorrelation. A possible reason is because this particular data set did not include its first point at t = −15 min because it was not shown in the graph found in the original article; see Figure 1b in Weyer et al, 7 where the x label of time starts at 0. Therefore, starting point for pramlintide at t = −15 min was unknown and baseline glucose was inferred. This is also reflected in Table 3 where the RMSE values are significantly higher than the other data sets found in Weyer et al. 7 The other data sets inclusive of t = 0 min, t = 15 min and t = 30 min showed randomness of residuals which indicates that the model includes sufficient information to capture the system. Some autocorrelation should be expected because there are effects due to glucagon that are not covered in our model. The runs test is very subjective with limited data and should not be done with less than 10 data points, 27 Weyer et al 7 contains 10 data points.
The remaining 20 PKPD data sets 13, 17, [22] [23] were used to validate the model, and covered a wide range of experimental conditions. The dosages of pramlintide varied from 10 micrograms to 300 micrograms. Time of pramlintide dosages varied from 30 minutes before a meal to 30 minutes after a meal was consumed. SC 7, 17, [22] [23] and IV 13 pramlintide boluses were evaluated. One study 17 included 3 meals over 24 hours and another 23 included 2 meals over 9 hours; both of these were predicted. Meals were either Sustacal 17, 22 or standardized. 7, 13, 23 The best RMSE values are 17.02 ± 3.19 and the worst RMSE values are 42.76 ± 8.07.
Fang et al 13 previously provided the most detailed PKPD model for pramlintide except was limited to IV infusions and boluses. The objective was to compare our developed SC PKPD model, which can be used for IV and SC infusions/ boluses of pramlintide to theirs. 13 Results are in Table 7 and Figure 9 show clearly that our model does better in the 30 
Conclusion
This nonlinear model utilizes ordinary differential equations as a means to describe the glucose-insulin-pramlintide physiological system of a T1DM patient. The model can be used to improve initial dosing as done in Micheletto et al. 24 but also can be used to explore other dosage regimens both in timing and quantity of the drugs. In the case of combined insulin/pramlintide therapy, the meal is extended significantly allowing more feedback to take place for additional corrective bolus(es) making glycemic regulation easier to obtain. In silico testing can readily be done to optimize possible new regimens. This compartmental model has the ability to be employed into a controller to improve current control approaches used in the artificial pancreas in which the timing and quantity of drugs can be varied based on a feedback system with the ability to adapt in real time. 
Glossary
States
SQ is1
Slow subcutaneous compartment 1
SQ if
Fast subcutaneous compartment 
